Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H4UP
|
|||
| Drug Name |
CAR-GPC3 T Cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Lung squamous cell carcinoma [ICD-11: 2C25.2] | Phase 1 | [1] | |
| Company |
Carsgen Therapeutics, Ltd.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glypican-3 (GPC3) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Proteoglycans in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Glypican pathway | |||
| Glypican 3 network | ||||
| Reactome | A tetrasaccharide linker sequence is required for GAG synthesis | |||
| HS-GAG degradation | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Visual phototransduction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02876978) Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.